This content is from: Patents
Brands fear effects of ANDA venue win – but should they?
BMS, Sanofi and others say a Federal Circuit ruling, if affirmed in a rehearing, could reshape Hatch-Waxman litigation. Others think it only affects Mylan
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here